Literature DB >> 1400376

Antagonistic effect of interferon-gamma on tat-induced transactivation of HIV long terminal repeat.

D Emilie1, M C Maillot, J F Nicolas, R Fior, P Galanaud.   

Abstract

Interferon-gamma (IFN-gamma) has been shown to inhibit human immunodeficiency virus (HIV) replication in macrophages. However, the site of its effect on the HIV infectious cycle is unknown. We show here that IFN-gamma inhibits the transactivation of HIV long terminal repeat (LTR) during viral infection and that it antagonizes tat effect in HT4LacZ-1 cells. HT4LacZ-1 is an indicator CD4+ HeLa cell line for HIV infectivity, because it harbors a HIV LTR-LacZ gene susceptible to transactivation by tat. It was used in combination with a computer-assisted image analyzer to quantify: (i) the number of transactivated foci following HIV infection, (ii) their individual level of transactivation, and (iii) the fusion potency of infected cells. IFN-gamma induced a 75% decrease of the number of transactivated foci following infection of HT4LacZ-1 cells by HIV. The remaining 25% foci still susceptible to transactivation were transactivated at a lower level than in control cultures, and the fusion potency of infected cells was strongly decreased. IFN-gamma acted after HIV entry into the cell and independently of reverse transcription. IFN-gamma antagonized tat-induced LTR transactivation: it inhibited transactivation of HT4LacZ-1 cells when tat was provided either from a SV40-based expression vector of tat or by polyethylene glycol-induced cell fusion with HeLa-tat-III cells. These results suggest that IFN-gamma affects the expression or the activity of cellular factors interacting with tat and that the high level of IFN-gamma production associated with HIV infection plays a role in the establishment of HIV latency.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400376

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Repression of retrovirus-mediated transgene expression by interferons: implications for gene therapy.

Authors:  S Ghazizadeh; J M Carroll; L B Taichman
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

2.  Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.

Authors:  Daria Trabattoni; Sergio Lo Caputo; Mara Biasin; Elena Seminari; Massimo Di Pietro; Giovanni Ravasi; Francesco Mazzotta; Renato Maserati; Mario Clerici
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

3.  Expression of IL-10, IL-4 and interferon-gamma in unstimulated and mitogen-stimulated peripheral blood lymphocytes from HIV-seropositive patients.

Authors:  F Diaz-Mitoma; A Kumar; S Karimi; M Kryworuchko; M P Daftarian; W D Creery; L G Filion; W Cameron
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

4.  Identifying potential survival strategies of HIV-1 through virus-host protein interaction networks.

Authors:  David van Dijk; Gokhan Ertaylan; Charles Ab Boucher; Peter Ma Sloot
Journal:  BMC Syst Biol       Date:  2010-07-15

5.  HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function.

Authors:  V Appay; D F Nixon; S M Donahoe; G M Gillespie; T Dong; A King; G S Ogg; H M Spiegel; C Conlon; C A Spina; D V Havlir; D D Richman; A Waters; P Easterbrook; A J McMichael; S L Rowland-Jones
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

6.  A rare case of an HIV-seronegative AIDS patient with Pneumocystis jirovecii pneumonia.

Authors:  Shuangquan Yan; Jing Huang; Qiaofei Zheng; Hongguo Zhu; Zhuolin Gao; Jiaxi Feng; Youzu Xu
Journal:  BMC Infect Dis       Date:  2019-06-14       Impact factor: 3.090

7.  Not all tetramer binding CD8+ T cells can produce cytokines and chemokines involved in the effector functions of virus-specific CD8+ T lymphocytes in HIV-1 infected children.

Authors:  Daniel Scott-Algara; Florence Buseyne; Françoise Porrot; Beatrice Corre; Nassima Bellal; Christine Rouzioux; Stephane Blanche; Yves Riviere
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.542

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.